Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).

被引：0
|
作者：
Stilgenbauer, S [1 ]
Winkler, D [1 ]
Kröber, A [1 ]
Kienle, D [1 ]
Hallek, M [1 ]
Hensel, M [1 ]
Lengfelder, E [1 ]
Trümper, L [1 ]
Dreger, P [1 ]
Jäger, U [1 ]
Döhner, H [1 ]
机构：
[1] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
478
引用
收藏
页码：140A / 140A
页数：1
相关论文
共 50 条
  • [31] Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Von Tresckow, Julia
    Fink, Anna-Maria
    Braun, Gracia
    Robrecht, Sandra
    Zhang, Can
    Tausch, Eugen
    Mueller, Lothar
    Knauf, Wolfgang
    Al-Sawaf, Othman
    Pelzer, Benedikt
    Langerbeins, Petra
    Fischer, Kirsten
    Kreuzer, Karl-Anton
    Ritgen, Matthias
    Kneba, Michael
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2020, 136
  • [32] Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)
    Koeppler, Hubert
    Fuss, Harald
    Hurtz, Hans J.
    Knigge, Owe
    Losem, Christoph
    Reschke, Daniel
    Schmitz, Stephan
    Weide, Rudolf
    Weiss, Johann
    Hallek, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 238 - 241
  • [33] CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Duehrsen, U
    Schulz, H
    Wendtner, CM
    Goebeler, ME
    Hallek, M
    BLOOD, 2005, 106 (11) : 601A - 601A
  • [34] Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group).
    Sayala, Hazem A.
    Moreton, Paul
    Jones, Richard A.
    Rawstron, Andy C.
    O'Connor, Sheila J.
    Evans, Paul
    Anthony, Carter
    Dearden, Claire
    Matutes, Estella
    Pettitt, Andrew R.
    Kennedy, Daniel B.
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 14A - 15A
  • [35] Prospective evaluation of prognostic parameters in early stage chronic lymphocytic leukemia (CLL): Results of the CLL1-protocol of the German CLL study group (GCLLSG)
    Bergmann, Manuela A.
    Eichhorst, Barbara F.
    Busch, Raymonde
    Adorf, Dagmar
    Stilgenbauer, Stephan
    Eckart, Michael J.
    Wendtner, Clemens-Martin
    Hallek, Michael
    BLOOD, 2007, 110 (11) : 193A - 193A
  • [36] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [37] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Lundin, J
    Björkholm, M
    Celsing, F
    Hale, G
    Hjalmar, V
    Kimby, E
    Tullgren, O
    Waldman, H
    Mellstedt, H
    Österborg, A
    ANNALS OF ONCOLOGY, 2000, 11 : 96 - 96
  • [38] CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
    Mellstedt, H
    Österborg, A
    Lundin, J
    Björkholm, M
    Celsing, F
    Hagberg, H
    Hast, R
    Hjalmar, V
    Kimby, E
    Luthman, M
    Tullgren, O
    Werner, B
    BLOOD, 1998, 92 (10) : 490A - 490A
  • [39] Development of a new, four-weekly schedule (FluCam) with concomittant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL.
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Engert, A
    BLOOD, 2002, 100 (11) : 803A - 803A
  • [40] CAMPATH-1H therapy in 29 patients with refractory CLL: "True" complete remission is an attainable goal.
    Kennedy, B
    Rawstron, AC
    Evans, P
    English, A
    Haynes, AP
    Russell, NH
    Byrne, J
    Hale, G
    Morgan, GJ
    Hillmen, P
    BLOOD, 1999, 94 (10) : 603A - 603A
12345